Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nephrogenic diabetes insipidus.

J P Morello1, D G Bichet

  • 1Department of Biochemistry, Université de Montréal, Montreal, Quebec, Canada. morelloj@ere.umontreal.ca

Annual Review of Physiology
|February 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

Molecular genetics and metabolism·2021
Same author

Vasopressin: physiology, assessment and osmosensation.

Journal of internal medicine·2017
Same author

Outcomes of patients treated through the Canadian Fabry disease initiative.

Molecular genetics and metabolism·2014
Same author

A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.

Molecular genetics and metabolism·2013
Same author

Inherited secondary nephrogenic diabetes insipidus: concentrating on humans.

American journal of physiology. Renal physiology·2013
Same author

Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases.

Nephron. Physiology·2010

Nephrogenic diabetes insipidus (NDI) is a kidney disorder impairing water reabsorption. Chaperone therapy shows promise in correcting protein misrouting, offering a potential treatment for NDI caused by genetic mutations.

Area of Science:

  • Nephrology
  • Human Genetics
  • Molecular Biology

Background:

  • Nephrogenic diabetes insipidus (NDI) is characterized by impaired kidney response to arginine vasopressin (AVP).
  • This condition leads to polyuria and polydipsia, despite normal or high AVP levels.
  • Congenital NDI is often X-linked, caused by mutations in the arginine vasopressin receptor 2 (AVPR2) gene, or less commonly autosomal, linked to aquaporin-2 (AQP2) gene mutations.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying inherited NDI.
  • To explore the potential of pharmacological chaperones as a therapeutic strategy for NDI.

Main Methods:

  • In vitro studies of mutant AVPR2 and AQP2 proteins.
  • Analysis of protein trafficking and function in response to mutations.

Related Experiment Videos

  • Assessment of chemical or pharmacological chaperones to correct protein misrouting.

    • Main Results:

    • Most AVPR2 mutations cause intracellular receptor retention, preventing cell surface expression.
    • Mutant AQP2 proteins are also misrouted, hindering water channel function.
    • Pharmacological chaperones effectively reversed intracellular retention of both AVPR2 and AQP2 mutants in vitro.

    Conclusions:

    • Genetic defects in AVPR2 and AQP2 disrupt protein trafficking, leading to NDI.
    • Pharmacological chaperones demonstrate potential in restoring the function of misrouted proteins.
    • This approach may offer a novel therapeutic avenue for hereditary diseases caused by protein kinesis errors.